Eli Lilly’s Foundayo Cuts 30.4 lbs, Retatrutide Delivers 19% Loss
LLY•Eli Lilly’s oral GLP-1 pill Foundayo achieved up to 14.4% bodyweight reduction (30.4 lbs) in perimenopausal women and 14.1% (28.2 lbs) in postmenopausal women over 72 weeks, with 51.5% of ATTAIN-1 participants losing at least 15%. Retatrutide’s 4 mg dose delivered 19% weight loss, bolstering Lilly’s obesity pipeline in a >$200B market.
1. Foundayo Shows Significant Weight Reduction Across Menopause Stages
Foundayo, Lilly’s first oral GLP-1 weight-loss pill, delivered an average 30.4-lb (14.4%) reduction in perimenopausal women and 28.2-lb (14.1%) in postmenopausal participants over 72 weeks in the ATTAIN-1 trial, with 51.5% achieving at least 15% bodyweight loss. In the ATTAIN-2 trial involving type 2 diabetes patients, postmenopausal women lost up to 27.8 lbs (13.6%), and waist circumference decreased by up to 4.9 inches.
2. Retatrutide Data Strengthens Obesity Pipeline
Retatrutide’s 4 mg dose produced a 19% average weight reduction in obese and type 2 diabetes patients across two trials, approaching the efficacy of Lilly’s highest Zepbound dose while maintaining tolerability. This improvement bolsters Lilly’s position in the obesity market, projected to exceed $200 billion, and supports the company’s leadership against other GLP-1 and obesity treatments.
